RT Journal Article
SR Electronic
T1 Alterations of lipid homeostasis in serum and white adipose tissue in morbid obese patients are partly reversed by the bariatric surgery
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.12.23291122
DO 10.1101/2023.06.12.23291122
A1 Sinturel, Flore
A1 Chera, Simona
A1 Brulhart-Meynet, Marie-Claude
A1 Montoya, Jonathan Paz
A1 Lefai, Etienne
A1 Jornayvaz, François R.
A1 D’Angelo, Giovanni
A1 Jung, Minoa Karin
A1 Pataky, Zoltan
A1 Riezman, Howard
A1 Dibner, Charna
YR 2023
UL http://medrxiv.org/content/early/2023/06/13/2023.06.12.23291122.abstract
AB Gastric Bypass surgery (GBS) represents a well-established approach to counteract human morbid obesity and its related comorbidities in modern countries. Beside its beneficial effect on weight loss and glucose homeostasis, emerging evidence suggests that GBS impacts on the circulating levels of phospho-and sphingolipids. However, long-term effects of GBS on lipid metabolism have not been explored. Thereby, we aimed to unveil to what extent GBS improves lipid homeostasis in serum and tissues from morbid obese individuals.To investigate alterations in lipidomic signatures associated with massive weight loss following GBS in morbid obese patients, we employed direct infusion tandem mass spectrometry (MS) allowing to quantify a wide range of lipid metabolites in serum and subcutaneous adipose tissue (SAT) samples. Systematic lipidomic analyses were conducted in samples collected in a longitudinal cohort of patients (cohort 1, n = 11) prior to GBS, and one year following the surgery. These novel data (cohort 1) were cross compared with our recent lipidomic analyses conducted by the same approach in an independent cohort of morbid obese patients and lean controls, where serum (n = 7 lean and n = 16 obese individuals) and visceral adipose tissue (VAT) (n = 5 control and n = 11 obese individuals) lipids were analysed (cohort 2).Over 400 phospholipid and sphingolipid species have been quantified in serum and SAT (cohort 1), allowing to establish detailed lipidomic signatures associated with morbid obesity in a tissue-specific manner. Concomitant with weight loss and improvement of metabolic parameters, a massive rearrangement of lipid metabolites was observed one year following GBS. Strikingly, a substantial reduction of ceramide levels and increased amount of hexosylceramides were detected in both serum and SAT. The comparison of these new lipidomic profiles with the serum and VAT lipidomes established from lean and morbid obese subjects (cohort 2) revealed that GBS partly restored the lipid alterations associated with morbid obesity.Our study provides the first systematic analysis of the long-term lipid homeostasis modifications upon GBS in humans SAT and serum and demonstrates that lipid metabolism alterations associated with morbid obesity might be partly reversed by GBS.The research protocols was registered with the Protocol Registration and Results System at ClinicalTrial.gov [NCT03029572].Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Swiss National Science Foundation grant 310030_184708/1, the Vontobel Foundation, the Novartis Consumer Health Foundation, EFSD/Novo Nordisk Programme for Diabetes Research in Europe, Swiss Life Foundation, the Olga Mayenfisch Foundation, Fondation pour l'innovation sur le cancer et la biologie and the SwissLife Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics committee of the University Hospital of Geneva gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors